



Simoa® ALZpath p-Tau 217 Advantage PLUS

Elevate Your Research with Quanterix Accelerator Lab Services

Quanterix's assays, combined with the expertise of our Accelerator Lab, empowers researchers to push the boundaries of Alzheimer's disease research. Unlock the potential for groundbreaking discoveries and contribute to the fight against neurodegenerative diseases with precision and confidence. Choose Quanterix today, and together, let's redefine Alzheimer's research for a brighter future.

Convenient Assay Kit Option

Take charge of your experiments with the [Simoa® ALZpath p-Tau 217 Advantage PLUS assay kit \(104570\)](#), designed for seamless implementation and precise p-Tau 217 quantification on the HD-X™. Our user-friendly protocols cater to researchers of all levels, ensuring a smooth and hassle-free assay setup in your own lab. Trust in robust and quantitative p-Tau 217 measurements, empowering you with comprehensive data to drive impactful research outcomes.

Pricing for p-Tau 217 Research

For detailed pricing information regarding the ALZpath p-Tau 217 Advantage PLUS assay, we encourage you to reach out to your dedicated Quanterix representative. Our team is committed to providing you with the most relevant and tailored pricing options to meet your specific needs. Contact us today to discuss how the ALZpath p-Tau 217 Advantage PLUS assay can elevate your research at sales@quanterix.com.

Empowering Your p-Tau 217 Research

Assay Platform	Quanterix Simoa®
Instrument	HD-X Analyzer
General Description	2-step digital enzyme immunoassay
Automation	Fully automated
Assay Timing	60-5 min
Capture Antibody	Rabbit monoclonal IgG: p-Tau 217
Detector Antibody	Mouse monoclonal IgG1 to the N-terminus of tau (441)
Calibrator Material	Synthetic peptide
Dynamic Range	0.007-30.0 pg/mL
Calibrator Points #	7 + blank
Calibrator Fitting	1/y ² weighted 5PL
Signal Enzyme/Substrate	Streptavidin-b-galactosidase (SBG)
Substrate	Resorufin-β-D-galacto pyranoside
Sample Type	Human plasma (EDTA)
Sample Volume	100 µL for duplicate testing (on-board)
Sample Dilution	3x
Limit of Detection	0.021pg/mL ¹ (corrected for dilution)
Limit of Quantification	0.060 pg/mL ¹ (corrected for dilution)
Intra-Run Precision (%CV)	2.8-6.8% (plasma, 2 runs, 40 reps) ¹
Inter-Run Precision (%CV)	14.9-20.3% (3 plasma spms, 20 days) ¹
Parallelism	Up to 8-fold dilution ¹
Clinical Accuracy CI A+T+	AUC 0.91 ^{2,3,4}
Clinical accuracy CU Ab	AUC 0.84 ^{2,3,4}

Citations

1. QTRX fit-for-purpose validation report
2. Theriault J, Ashton NJ, Pola I, et al. Comparison of Two Plasma P-Tau217 Assays to Detect and Monitor Alzheimer's Pathology. Preprint available at SSRN: <https://ssrn.com/abstract=4572850> or <http://dx.doi.org/10.2139/ssrn.4572850>
3. Brum WS, Ashton NJ, Simrén J, et al. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals. *Alzheimers Dement*. Published online November 20, 2023. doi:10.1002/alz.13518
4. Xiao Z, Wu W, Ma X, et al. Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study. *Alzheimers Dement (Amst)*. 2023;15(4):e12514. Published 2023 Dec 22. doi:10.1002/dad2.12514

For more information:

www.quanterix.com | sales@quanterix.com | 617-301-9400